Aesthetic plastic surgery · 2025
Longitudinal Assessment of Masseter Muscle Elasticity Changes After BoNT-A Injection Using Ultrasound Elastography: A Prospective Self-Controlled Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yan Mengyue, Luo Yuna, Wu Qian, Zhao Minghao, Qiu Yuzhi, Chai Hongli, Jia Ying, Yu Panxi, Lu Jianjian
Аннотация
BACKGROUND: Botulinum neurotoxin type A (BoNT-A) is widely used to treat masseter hypertrophy, but its long-term structural effects remain unclear. While animal studies suggest reversible and irreversible remodeling, human data on microstructural changes are limited. Ultrasound elastography (USE) offers a non-invasive method to quantitatively assess muscle elasticity and detect fibrosis risk.
METHODS: A prospective self-controlled trial enrolled 14 subjects (28 masseter muscles) aged 21-27 years. Masseter thickness and standardized USE measurements (shear wave velocity, V median) were performed at baseline and 1, 3, and 6 months post-injection. Statistical analysis included paired t-tests and Spearman correlation.
RESULTS: Masseter thickness decreased significantly by 28.9-31.5% at 1-3 months (p ≤ 0.05), with partial recovery (47.4%) by 6 months. V median (elasticity) declined at 1-3 months (2.53 ± 0.46 m/s to 2.10 ± 0.45 m/s, p ≤ 0.05), but returned to baseline by 6 months (2.70 ± 0.68 m/s, p > 0.05), indicating reversible structural adaptation. Thickness and elasticity changes were uncorrelated, suggesting distinct recovery mechanism.
CONCLUSION: BoNT-A induces transient masseter atrophy and elasticity reduction, with full elastic recovery by 6 months despite incomplete volume restoration. USE effectively tracks reversible microstructural remodeling, distinguishing atrophy from fibrosis. These findings support USE as a tool for optimizing injection timing and monitoring functional recovery.
LEVEL OF EVIDENCE II: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
METHODS: A prospective self-controlled trial enrolled 14 subjects (28 masseter muscles) aged 21-27 years. Masseter thickness and standardized USE measurements (shear wave velocity, V median) were performed at baseline and 1, 3, and 6 months post-injection. Statistical analysis included paired t-tests and Spearman correlation.
RESULTS: Masseter thickness decreased significantly by 28.9-31.5% at 1-3 months (p ≤ 0.05), with partial recovery (47.4%) by 6 months. V median (elasticity) declined at 1-3 months (2.53 ± 0.46 m/s to 2.10 ± 0.45 m/s, p ≤ 0.05), but returned to baseline by 6 months (2.70 ± 0.68 m/s, p > 0.05), indicating reversible structural adaptation. Thickness and elasticity changes were uncorrelated, suggesting distinct recovery mechanism.
CONCLUSION: BoNT-A induces transient masseter atrophy and elasticity reduction, with full elastic recovery by 6 months despite incomplete volume restoration. USE effectively tracks reversible microstructural remodeling, distinguishing atrophy from fibrosis. These findings support USE as a tool for optimizing injection timing and monitoring functional recovery.
LEVEL OF EVIDENCE II: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .